Comparative Efficacy of Different Biologic Agents on Radiographic Progression in Patients with Rheumatoid Arthritis: A Network Meta-Analysis
Archivum Immunologiae et Therapiae Experimentalis · 01.01.2026 · 74 (1)
DOI: 10.2478/aite-2026-0028 ↗Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift Archivum Immunologiae et Therapiae Experimentalis, online erschienen am 10.11.2026. Verfasst von Di Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, Jilin 130021, China. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents, Biological Products. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Radiographic progression in rheumatoid arthritis (RA) reflects irreversible joint damage. Whether different classes of biologic disease-modifying antirheumatic drugs (bDMARDs) offer comparable structural protection remains uncertain. To compare six bDMARD classes (tumor necrosis factor [TNF]-α inhibitors, interleukin [IL]-17 inhibitors, T-cell co-stimulation modulators, B-cell depleting agents, IL-6 receptor antagonists, and IL-23 inhibitors) in suppressing radiographic progression in RA. PubMed, Embase, Web of Science, and CENTRAL were searched to 31 December 2025 for randomized controlled trials (RCT); change in modified Total Sharp Score (mTSS) at 12 months was the primary outcome. A Bayesian random-effects network meta-analysis was fitted, with SUCRA-based ranking. 27 RCTs (11,650 patients) were included. All six classes significantly inhibited mTSS progression versus placebo. Relative to TNF-α inhibitors (TNF-i), greater inhibition was seen with B-cell depleting agents (mean difference [MD] = −18.46, 95% CI −20.86 to −16.06), IL-23 inhibitors (MD = −18.14, 95% CI −21.11 to −15.16), IL-17 inhibitors (MD = −15.67), T-cell co-stimulation modulators (MD = −14.99) and IL-6 receptor antagonists (MD = −13.73); the first two were also superior to IL-6 receptor antagonists. For bone erosion (13 RCTs), IL-17, B-cell depleting, IL-6 receptor and T-cell agents, but not IL-23 inhibitors, were superior to TNF-i. For ACR20 (20 RCTs), IL-23 (OR = 2.75, 95% CI 1.31–5.76), IL-6 (OR = 2.12) and IL-17 (OR = 1.86) inhibitors were superior to TNF-i. Serious adverse events (10 RCTs) did not differ from placebo. B-cell depleting agents and IL-23 inhibitors ranked highest; as several comparisons rest on few trials, this ordering is hypothesis generating.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, Jilin 130021, China.
Zitieren
APA
Liu, D., Yuan, N., Yu, G., & Nie, D. (2026). Comparative Efficacy of Different Biologic Agents on Radiographic Progression in Patients with Rheumatoid Arthritis: A Network Meta-Analysis. Archivum Immunologiae et Therapiae Experimentalis, 74(1). https://doi.org/10.2478/aite-2026-0028
Vancouver
Liu D, Yuan N, Yu G, Nie D. Comparative Efficacy of Different Biologic Agents on Radiographic Progression in Patients with Rheumatoid Arthritis: A Network Meta-Analysis. Archivum Immunologiae et Therapiae Experimentalis. 2026;74(1). doi:10.2478/aite-2026-0028
BibTeX
@article{Liu2026,
author = {Liu, Di and Yuan, Na and Yu, Guimei and Nie, Daqing},
title = {Comparative Efficacy of Different Biologic Agents on Radiographic Progression in Patients with Rheumatoid Arthritis: A Network Meta-Analysis},
journal = {Archivum Immunologiae et Therapiae Experimentalis},
year = {2026},
volume = {74},
number = {1},
doi = {10.2478/aite-2026-0028}
}
EUVIMED